Tags

Type your tag names separated by a space and hit enter

Pharmacologic management of obsessive-compulsive disorder.
South Med J. 1994 Mar; 87(3):310-21.SM

Abstract

Obsessive-compulsive disorder (OCD) is an intriguing, difficult problem characterized by anxiety-producing intrusive thoughts and performance of anxiety-reducing rituals. Current evidence suggests that OCD may be associated with dysregulation of serotonin and dopamine neurotransmission. Numerous early studies involving the serotonin-specific reuptake inhibitor clomipramine led to the formulation of this hypothesis. Positive results with clomipramine initiated further research with other serotonin-specific reuptake inhibitors, such as fluoxetine, fluvoxamine, sertraline, and serotonergic agents such as buspirone and trazodone. Findings from a number of clinical trials suggest that drugs that inhibit serotonin reuptake or affect serotonergic transmission in other ways are of clear benefit in the treatment of OCD. These drugs may be more effective for obsessive thoughts than for compulsive rituals. Effective pharmacotherapy can dramatically decrease obsessive-compulsive symptoms and improve the patient's quality of life.

Authors+Show Affiliations

Department of Hospital Pharmacy Practice and Administration, Medical University of South Carolina, Charleston 29425.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8134850

Citation

Jackson, C W., et al. "Pharmacologic Management of Obsessive-compulsive Disorder." Southern Medical Journal, vol. 87, no. 3, 1994, pp. 310-21.
Jackson CW, Morton WA, Lydiard RB. Pharmacologic management of obsessive-compulsive disorder. South Med J. 1994;87(3):310-21.
Jackson, C. W., Morton, W. A., & Lydiard, R. B. (1994). Pharmacologic management of obsessive-compulsive disorder. Southern Medical Journal, 87(3), 310-21.
Jackson CW, Morton WA, Lydiard RB. Pharmacologic Management of Obsessive-compulsive Disorder. South Med J. 1994;87(3):310-21. PubMed PMID: 8134850.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacologic management of obsessive-compulsive disorder. AU - Jackson,C W, AU - Morton,W A, AU - Lydiard,R B, PY - 1994/3/1/pubmed PY - 1994/3/1/medline PY - 1994/3/1/entrez SP - 310 EP - 21 JF - Southern medical journal JO - South. Med. J. VL - 87 IS - 3 N2 - Obsessive-compulsive disorder (OCD) is an intriguing, difficult problem characterized by anxiety-producing intrusive thoughts and performance of anxiety-reducing rituals. Current evidence suggests that OCD may be associated with dysregulation of serotonin and dopamine neurotransmission. Numerous early studies involving the serotonin-specific reuptake inhibitor clomipramine led to the formulation of this hypothesis. Positive results with clomipramine initiated further research with other serotonin-specific reuptake inhibitors, such as fluoxetine, fluvoxamine, sertraline, and serotonergic agents such as buspirone and trazodone. Findings from a number of clinical trials suggest that drugs that inhibit serotonin reuptake or affect serotonergic transmission in other ways are of clear benefit in the treatment of OCD. These drugs may be more effective for obsessive thoughts than for compulsive rituals. Effective pharmacotherapy can dramatically decrease obsessive-compulsive symptoms and improve the patient's quality of life. SN - 0038-4348 UR - https://www.unboundmedicine.com/medline/citation/8134850/Pharmacologic_management_of_obsessive_compulsive_disorder_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=8134850.ui DB - PRIME DP - Unbound Medicine ER -